Drug Profile
Research programme: GPR 119 agonists - Boehringer Ingelheim/Neurocrine Biosciences
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Neurocrine Biosciences
- Class Small molecules
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA
- 22 Feb 2011 Early research is ongoing in USA
- 18 Jun 2010 Early research in Type-2 diabetes mellitus in USA (unspecified route)